Mycotopia Therapies, Inc. financial data

Symbol
TPIA on OTC
Industry
Medicinal Chemicals & Botanical Products
Location
480 22 Nd Street, Heyburn, ID
State of incorporation
NV
Fiscal year end
December 31
Former names
20/20 Global, Inc. (to 5/19/2021)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 7.94 % -76%
Debt-to-equity -172 % -24.1%
Return On Equity 65.5 % -56.1%
Return On Assets -91.1 % +76.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.9M shares 0%
Common Stock, Shares, Outstanding 14.9M shares 0%
Entity Public Float 1.55M USD -75.1%
Common Stock, Value, Issued 14.9K USD +0.01%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.11M USD +54.6%
Operating Income (Loss) -1.11M USD -54.6%
Nonoperating Income (Expense) -390K USD +48.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.5M USD -1.24%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.5M USD -1.24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 438K USD -53.7%
Assets, Current 280K USD -17.3%
Property, Plant and Equipment, Net 0 USD
Assets 1.89M USD +455%
Accrued Liabilities, Current 375K USD
Liabilities, Current 4.81M USD +172%
Liabilities 4.81M USD +172%
Retained Earnings (Accumulated Deficit) -9.86M USD -17.9%
Stockholders' Equity Attributable to Parent -2.92M USD -105%
Liabilities and Equity 1.89M USD +455%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73.7K USD -155%
Net Cash Provided by (Used in) Financing Activities 165K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 14.9M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 215K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 280K USD -17.4%
Deferred Tax Assets, Valuation Allowance 552K USD +51.9%
Cash and Cash Equivalents, Period Increase (Decrease) 215K USD
Deferred Tax Assets, Gross 552K USD +51.9%
Depreciation 498 USD +0.61%
Deferred Tax Assets, Operating Loss Carryforwards 268K USD +29.5%
Preferred Stock, Shares Authorized 5M shares
Additional Paid in Capital 6.92M USD 0%
Interest Expense 79.3K USD -50.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares